Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 9Neoplasms 3Brain Neoplasms 3Medulloblastoma 2Glioma 2Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6Biopsy 6X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 4Cisplatin 3Carboplatin 3tazemetostat 2selpercatinib 2larotrectinib 2erdafitinib 2entrectinib 2ensartinib 2cabozantinib 2Topotecan 2Temozolomide 2Surveys and Questionnaires 2Radiation 2LY3023414 2Gemcitabine 2Etoposide 2Cyclophosphamide 2ulixertinib 1tipifarnib 1pegfilgrastim 1palbociclib 1olaparib 1niraparib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Lomustine × 90 days × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡